Cybin D/B/A Helus Pharma (HELP)
Nasdaq · Healthcare · Biotechnology
$11.42−2.39%as of Oct 6, 2026, 1:35 AM ET
- Market cap
- $834M
- 52-week range
- $3.76 – $15.15
- 52-week change
- +81.96%
- EPS (trailing)
- −$4.15
- Analyst rating
- 1.1 Strong buy
- Next earnings
- Nov 12, 2026
About Cybin D/B/A Helus Pharma
Helus Pharma Inc., doing business as Helus Pharma, a clinical stage pharmaceutical company, focuses on developing therapies to treat various psychiatric and neurological conditions. It develops HLP003, a deuterated psilocybin analog, which is in phase 3 clinical trial to treat major depressive disorder (MDD); and HLP004, a deuterated N, N-dimethyltryptamine (DMT), which is in phase 2 clinical trial for treating generalized anxiety disorders. The company' preclinical product includes HLP005, a phenethylamine and tryptamine derivative to treat central nervous system. It has a strategic partnership agreement with Segal Trials to evaluating HLP003 for the adjunctive treatment of major depressive disorder; and with Osmind for mental health treatments. The company was formerly known as Cybin Inc. and changed its name to Helus Pharma Inc. in October 2026. The company was founded in 2019 and is headquartered in Toronto, Canada.
Headquarters: Toronto, Canada · 100 employees · helus.com